Advertisement

Topics

LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression

09:11 EST 19 Feb 2019 | Compelo Medical Devices

Per its final decision, CMS has modified the NCD for VNS Therapy for TRD to include feedback received during the comment period in a manner that aligns the

The post LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression appeared first on Compelo Medical Devices.

Original Article: LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression

NEXT ARTICLE

More From BioPortfolio on "LivaNova recognizes final decision from US CMS for NCD of VNS Therapy for treatment-resistant depression"

Advertisement
Quick Search
Advertisement
Advertisement